In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

NephRx Corporation

Latest From NephRx Corporation

The Year In Review: Device Trends To Watch In 2014

To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries, but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.

Medical Device Business Strategies

Medtech 2013: Device Companies Go Where The Growth Is

To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.

Medical Device

Start-Up Previews (6/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Gene Delivery, features profiles of ImaRx Therapeutics Inc., Intradigm Corp., Protiva Biotherapeutics Inc. and Tranzyme Inc. Plus these Selected Start-Ups across Health Care: FASgen Inc., Power Medical Interventions Inc., NephRx Corp. and Tessera Diagnostics Inc.

NephRx Corp.

Although no one has yet developed a drug for kidney failure, researchers have long maintained the hope that reversing kidney failure is an attainable goal, because the kidney is one of the few organs in the body capable of regenerating. NephRx Corp. is one of this number of hopefuls; it believes its family of growth factors will repair damaged renal cells, and potentially also serve in degenerative gastrointestinal disorders.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register